Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

prnasiaFebruary 18, 2021

Tag: EmpathBio , Bionomics , BNC210 , EMP-01 , PTSD

PharmaSources Customer Service